Piper says Alexion early approval should help continue complement ‘dominance’

Piper Jaffray analyst Christopher Raymond notes that expectations were for Ultomiris to be approved in February, meaning today’s decision came roughly two months early, which will pull forward the timeline for Alexion’s market conversion from Soliris to Ultomiris. The earlier than expected approval, along with the “high bar Ultomiris has set,” positions Alexion to “continue its dominance in the complement space,” said Raymond. He maintains an Overweight rating and $177 price target on Alexion shares.
https://thefly.com/landingPageNews.php?id=2840717